Cognition, memory, and focus is the main area connected here, and any felt benefit should be read together with the human evidence base.
The 52.5 score includes research signals from patient or disease contexts. General supplement evidence is not repeated enough, so the C tier remains conservative.
Representative tier calculated from paper evidence that passed the collection audit.
The representative ingredient tier is calculated from these target-level evidence groups.
Potential benefit studied in Cognition and focus. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
This card is closer to a measured biomarker or lab outcome than a directly felt user benefit. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
Potential benefit studied in Immune and respiratory health. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
Potential benefit studied in Blood lipids. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
Potential benefit studied in Cardiovascular outcomes. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
These findings come from sperm, semen, or hormone markers such as testosterone, LH, FSH, and inhibin B. They are closer to research measurements than a directly felt benefit. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
This range includes studies in specific patient groups. It is not a general dose or recommendation.
Findings from studies of this ingredient alone are separated from findings involving another supplement or medication.
Side effects reported for the ingredient alone are separated from findings involving another supplement or medication.
Symptoms or adverse events reported in studies of this ingredient without another active ingredient.
Positive combination findings are separated by how the study compared the groups. This is not a recommendation to combine them.
The combination had a positive result, but the contribution of each ingredient could not be separated.
Paper IDs and full lists are private. Only study types and summaries are shown.
Among statin-treated patients at high cardiovascular risk, the addition of omega-3 CA, compared with corn oil, to usual background therapies resulted in no significant difference in a composite outcome of major adverse cardiovascular events.
The pooled data suggest that omega-3 PUFA supplementation may decrease liver fat, however, the optimal dose is currently not known.
The ongoing VITamin D and OmegA-3 TriaL (VITAL) is a large randomized, double-blind, placebo-controlled, 2×2 factorial trial of vitamin D and marine omega-3 fatty acids in the primary prevention of cancer and CVD among a multi-ethnic population of 20,000 U.S.
The cumulative evidence from RCTs designed to assess the effect of omega-3 polyunsaturated fatty acid supplementation on clinical cardiovascular events is reviewed and prior recommendations for patients with prevalent coronary heart disease are updated.
All the new sources have potentially important roles to play in increasing the supply of n-3 LC-PUFA so that they are available more widely and in higher concentrations providing more options and opportunities for human consumers to obtain sufficient EPA and D
Erythrocyte membrane EPA+DHA increases during relatively short intervals in response to supplementation at rates related to amount of supplementation, and may be useful to establish appropriate dosage for omega-3 fatty acid supplementation.